在Rituximab耐药和复发性膜性脏病中使用Obinutuzumab:一个病例系列
Krita Sridharan1,2, Basu Gopal3,4, Scott Wilson5
1Department of Nephrology, St Vincent's Hospital, Melbourne, VIC, Australia. krita.sri@gmail.com.
Journal of nephrology
|February 20, 2025
概括
奥比努图祖马布在治疗抗性膜性病,特别是抗脂酶A2受体 (PLA2R) 病例方面表现有前途. 这项研究在PLA2R阳性患者中发现完全缓解,支持其在难以治疗的病例中使用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜性病 (MN) 是成年人性综合征的主要原因.
- 未经治疗的MN具有进展到末期脏疾病的高风险.
- 利图西马布是一种常见的治疗方法,但许多患者表现出耐药性.
研究的目的:
- 评估Obinutuzumab在患有抗治疗膜性病症的患者中的疗效.
- 为了评估结果,无论抗脂酶A2受体 (PLA2R) 抗体状态如何.
主要方法:
- 在澳大利亚墨尔本进行了一系列单中心病例.
- 这项研究包括了所有在2023年1月至2024年6月期间因膜性病接受Obinutuzumab治疗的患者.
- 不管PLA2R状态如何,都分析了患者数据.
主要成果:
- 五分之三的患者患有与PLA2R相关的MN,对Rituximab耐火.
- 这三名PLA2R阳性患者都通过Obinutuzumab获得了完全的免疫和临床缓解.
- 一例二次性PLA2R阴性MN的病例实现了部分缓解,一例在移植中复发的MN没有反应.
结论:
- 这一案例系列证实了Obinutuzumab在抗治疗的PLA2R相关膜性腎病症中的有效性.
- 这项研究报告了Obinutuzumab在沙尔科毒症相关的膜性脏病中首次使用.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
330
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...